In addition, GAS2 silencing did not disturb the growth of normal CD3+ or CD34+ cells, which supports GAS2 as a suitable therapeutic target to eradicate T‐ALL cells or other hematological malignancies with aberrant GAS2 expression, such as CML and myeloproliferative neoplasm [12, 15, 53]. Here, CD34 is linked to hematologic disorder.